Literature DB >> 7767261

Is there a rationale for high-dose chemotherapy as first line treatment of advanced Hodgkin's disease? German Hodgkin's Lymphoma Study Group (GHSG).

D Hasenclever1, N Schmitz, V Diehl.   

Abstract

Entities:  

Mesh：

Year:  1995        PMID： 7767261     DOI： 10.3109/10428199509052706

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  2 in total

1.  Prognostic factors for disease progression in advanced Hodgkin's disease: an analysis of patients aged under 60 years showing no progression in the first 6 months after starting primary chemotherapy.

Authors:  S M Lee; J A Radford; W D Ryder; C D Collins; D P Deakin; D Crowther
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

2.  Plasma levels of tumour necrosis factor and its soluble receptors correlate with clinical features and outcome of Hodgkin's disease patients.

Authors:  K Warzocha; J Bienvenu; P Ribeiro; I Moullet; C Dumontet; E M Neidhardt-Berard; B Coiffier; G Salles
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.